PDCD1 and breast carcinoma: However, owing to the significant differences in immune cell infiltration and immune response in breast cancer, many patients with PD-1+ cancers fail to show a long-pasting suppressive response to PD-1 [9, 10], and overcoming this challenge continues to be a bottleneck in cancer treatment.